Wednesday, December 02, 2020 CCTG is sends a big congratulations to all of the TMIST participating centres in Canada. Just twelve weeks later after 4000 subjects were accrued in late August, we have reached another BIG milestone for the MAC22 study: more than 5000 are enrolled in Canada! "MAC22 continues to enroll beyond expectations and has made a significant contribution to the overall trial accrual. TMIST is a very large North American screening study for breast cancer and Canada, through the efforts of only 6 centres, has contributed 15% of the current accrual to the trial. In Canada the highest recruiting centre is Hopital du sacre-coeur de Montreal under the leadership of Dr. Caroline Samson. Congratulations to all!" says Dr. Lois Shepherd, the CCTG Senior Investigator for the trial. About the trial The Tomosynthesis Mammographic Imaging Screening Trial (TMIST), is the first randomized trial to compare two types of digital mammography for breast cancer screening: tomosynthesis (known as three-dimensional, or 3-D) and conventional (two-dimensional, or 2-D). Although 3-D mammography, is a newer technology it will likely detect more findings that require follow-up, it is also likely to lead to more procedures and treatments. It is not known if this newer mammography technology is reducing a woman’s risk of developing a life-threatening (advanced) cancer compared with 2-D mammography. At participating centers, women (45 to 75) will be told about the trial when they schedule their routine mammogram and once enrolled are then randomly assigned to either 2-D or 3-D mammography screening for the next five years. To find out more about the trial visit the MAC22 trial page
